UnitedHealthcare is incorporating real-world evidence into pathways design and policy formulation, leveraging its members' data to evaluate the impact of different regimens on health resource utilization and costs, explains Lucy Langer, MD, MSHS, national medical director of oncology and genomics at UnitedHealthcare.
Lucy Langer, MD, MSHS, national medical director of oncology and genomics at UnitedHealthcare, talks about how UnitedHealthcare is incorporating real-world evidence into pathways design and policy formulation, leveraging its members' data to evaluate the impact of different regimens on health resource utilization and costs.
Transcript
With real-world evidence becoming increasingly important in decision-making related to cancer drug and testing reimbursement, how is UnitedHealthcare integrating it into its reimbursement policies?
Real-world evidence is becoming increasingly important, as you said, and we use it in our pathways design. When we have 2 regimens that are equivalent, as I mentioned before, we use the real-world evidence that we have with United members to look at how each regimen impacts utilization of health resources and cost, of course.
In our policies, we also use real-world evidence. So, when we write policies or we review policies or renew them, we're looking very carefully at how the policy is impacting the member population, what the utilization rates are, and how those policies play out in the real-world evidence. I think there's a lot of room to go with real-world evidence, and in particular, when we're thinking about molecular testing, for example, I think we can really leverage more of that to help determine the best test for the right patient at the right time.
What specific challenges or opportunities have you encountered when incorporating real-world evidence into your decision-making processes?
I think that the real-world evidence limitations are similar to limitations from clinical trials, but on a bigger scale. So, with clinical trial data you always wonder, does that trial apply directly to my patient? And with real-world evidence, it's a question of, are we defining the populations correctly, and are we getting the right patients or the right members in that evidence block to really inform the question that we're trying to answer?
I think we are limited in any particular institution where we're doing real-world evidence with our own data, is that it's only our own data. So, from a payer perspective, when you're looking at real-world evidence, you're looking at members that might go in and out of coverage, they might go from one payer to another or one employer to another, their information may be lost along the way. So we are always looking at a somewhat incomplete picture.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More
AUA to Focus on Inclusive Care, Robotic Surgeries, and Future of Urology at 2024 Annual Meeting
May 1st 2024The American Urological Association (AUA) 2024 Annual Meeting will highlight the latest innovations and future trends in urology, featuring dynamic plenary sessions, educational opportunities for providers, and discussions on cutting-edge treatments and global health initiatives.
Read More